Search

everythinglearnresearchcommunity

for

Search:↓

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

ACTH may be an effective first-line treatment for acute calcium pyrophosphate crystal arthritis.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Baricitinib was effective in treating alopecia areata in two major trials.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

Axitinib treatment turned a man's grey hair back to black.